Opiant Pharmaceuticals (OPNT) 10-K 15 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 14, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-38193
Entity Registrant Name	OPIANT PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4744124
Entity Address, Address Line One	233 Wilshire Blvd.
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90401
City Area Code	310
Local Phone Number	598-5410
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 55,174,019
Entity Common Stock, Shares Outstanding		5,069,605
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0001385508
Trading Symbol	OPNT

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas
Auditor Firm ID	206

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 37,853,947	$ 48,251,336
Marketable securities	15,014,750	0
Accounts receivable	13,327,364	8,910,975
Prepaid expenses and other current assets	2,962,903	1,936,842
Total current assets	69,158,964	59,099,153
Non-current assets
Property and equipment, net	78,107	171,190
Right of use assets - operating leases	999,567	278,455
Patents and patent applications, net	11,628	13,000
Other non-current assets	179,532	1,051,234
Total assets	70,427,798	60,613,032
Current liabilities
Accounts payable and accrued liabilities	3,369,848	2,966,479
Accrued salaries and wages	201,254	908,516
Royalty payable	2,920,148	1,908,072
Deferred revenue	16,618	354,756
Operating leases - current	337,690	282,421
Total current liabilities	6,845,558	6,420,244
Long-term liabilities
Operating leases - long term	673,347	0
Convertible debt, net of unamortized discount	16,069,085	18,700,546
Total liabilities	23,587,990	25,120,790
Stockholders' equity
Common stock; par value $0.001; 200,000,000 shares authorized; 4,909,846 and 4,258,105 shares issued and outstanding at December 31, 2021 and 2020, respectively.	4,910	4,259
Additional paid-in capital	108,569,988	100,203,979
Accumulated other comprehensive loss	(54,815)	(26,931)
Accumulated deficit	(61,680,275)	(64,689,065)
Total stockholders' equity	46,839,808	35,492,242
Total liabilities and stockholders' equity	$ 70,427,798	$ 60,613,032

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	4,909,846	4,258,105
Common stock, shares outstanding (in shares)	4,909,846	4,258,105

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues
Royalty revenue	$ 40,725,185	$ 27,401,919
Grant and contract revenue	7,060,293	2,223,262
Total revenue	47,785,478	29,625,181
Operating expenses
General and administrative	12,152,935	11,742,540
Research and development	16,833,537	9,240,020
Sales and marketing	4,576,263	4,686,932
Royalty expenses	9,066,432	6,196,706
Total operating expenses	42,629,167	31,866,198
Income (loss) from operations	5,156,311	(2,241,017)
Other income (expense)
Interest income, net	11,402	93,877
Interest expense	(2,128,962)	(131,007)
Loss on foreign exchange	(5,691)	(8,981)
Total other income (expense)	(2,123,251)	(46,111)
Income (loss) before income taxes	3,033,060	(2,287,128)
Income tax (expense) benefit	(24,270)	425,679
Net income (loss)	3,008,790	(1,861,449)
Other comprehensive income (loss)
Foreign currency translation adjustments	(27,884)	(26,931)
Total comprehensive income (loss)	$ 2,980,906	$ (1,888,380)
Income (loss) per share of common stock:
Basic (in dollars per share)	$ 0.68	$ (0.44)
Diluted (in dollars per share)	$ 0.51	$ (0.44)
Weighted average common stock outstanding
Basic (in shares)	4,456,162	4,249,832
Diluted (in shares)	5,920,069	4,249,832

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2019		4,186,438
Beginning Balance at Dec. 31, 2019	$ 34,416,026	$ 4,187	$ 97,239,455	$ 0	$ (62,827,616)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		12,157
Exercise of stock options	90,000	$ 12	89,988
Exercise of warrants (in shares)		59,510
Exercise of warrants	595,100	$ 60	595,040
Debt issuance cost associated with debt conversion	0
Stock based compensation	2,279,496		2,279,496
Foreign currency translation adjustment	(26,931)			(26,931)
Net income (loss)	(1,861,449)
Ending Balance (in shares) at Dec. 31, 2020		4,258,105
Ending Balance at Dec. 31, 2020	35,492,242	$ 4,259	100,203,979	(26,931)	(64,689,065)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		448,847
Exercise of stock options	2,718,940	$ 448	2,718,492
Exercise of warrants (in shares)		71,667
Cashless exercise of stock (in shares)		27,076
Cashless exercise of stock	0	$ 27	(27)
Restricted stock issued ( in shares)		19,902
Restricted stock issued	0	$ 20	(20)
Stock issued from converted debt ( in shares )		155,916
Stock issued from converted debt	3,062,200	$ 156	3,062,044
Debt issuance cost associated with debt conversion	(162,780)		(162,780)
Stock based compensation	2,748,300		2,748,300
Foreign currency translation adjustment	(27,884)			(27,884)
Net income (loss)	3,008,790				3,008,790
Ending Balance (in shares) at Dec. 31, 2021		4,909,846
Ending Balance at Dec. 31, 2021	$ 46,839,808	$ 4,910	$ 108,569,988	$ (54,815)	$ (61,680,275)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows provided by (used in) operating activities
Net income (loss)	$ 3,008,790	$ (1,861,449)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	94,456	123,680
Amortization of debt discount	267,959	16,487
Operating leases amortization	567,078	484,793
Stock based compensation expense	2,748,300	2,279,496
Changes in assets and liabilities:
Accounts receivable	(4,416,390)	(1,692,607)
Prepaid expenses and other current assets	(157,800)	(1,918,109)
Accounts payable and accrued liabilities	308,131	1,636,326
Accrued salaries and wages	(596,929)	(338,352)
Operating lease liabilities	(571,044)	(483,412)
Royalty payable	1,012,076	287,890
Deferred revenue	(338,138)	(563,516)
Net cash provided by (used in) operating activities	1,926,489	(2,028,773)
Cash flows used in investing activities
Purchase of marketable securities	(15,014,750)	0
Purchase of property and equipment	0	(50,887)
Net cash used in investing activities	(15,014,750)	(50,887)
Cash flows provided by financing activities
Proceeds from debt issuance	0	20,000,000
Debt issuance costs	0	(1,315,941)
Proceeds from exercise of options and warrants	2,718,940	685,100
Net cash provided by financing activities	2,718,940	19,369,159
Effect of foreign currency translation on cash	(28,068)	(18,636)
Net (decrease) increase  in cash and cash equivalents	(10,397,389)	17,270,863
Cash and cash equivalents, beginning of year	48,251,336	30,980,473
Cash and cash equivalents, end of year	37,853,947	48,251,336
Supplemental disclosure
Interest paid during the year	1,535,617	0
Taxes paid during the year	0	39,000
Non-Cash Investing and Financing Transactions
Cashless exercise of options	27	2
Issuance of restricted stock	20
Common stock issued for debt conversion	3,062,200	0
Debt issuance cost associated with debt conversion	162,780	0
Right of use assets obtained in exchange for new lease obligations	$ 1,189,168	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation    Opiant Pharmaceuticals, Inc. (the “Company”), a Nevada corporation, is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company was incorporated in the State of Nevada on June 21, 2005 as Madrona Ventures, Inc. and, on September 16, 2009, the Company changed its name to Lightlake Therapeutics Inc. On January 28, 2016, the Company again changed its name to Opiant Pharmaceuticals, Inc. The Company also has developed a treatment to reverse opioid overdoses, which is now known as NARCAN®. On October 2, 2017, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to an Agreement and Plan of Merger, dated October 2, 2017, whereby the Company merged with and into its recently formed, wholly-owned Delaware subsidiary, Opiant Pharmaceuticals, Inc.

Liquidity and Financial Conditi

Liquidity and Financial Condition	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Financial Condition	Liquidity and Financial Condition The Company had net income of $3.0 million for the year ended December 31, 2021 and has an accumulated deficit of $61.7 million at December 31, 2021. The Company had $62.3 million of working capital at December 31, 2021. The Company has financed its operations from sale of Common Stock, convertible debt, and through non-equity cash investments by a number of investors, in exchange for an interest in any pre-tax profits received by the Company that was derived from the sale of the Opioid Overdose Reversal Treatment Product less any and all expenses incurred by and payments made by the Company in connection with the Opioid Overdose Reversal Treatment Product ("OORT"). During the year ended December 31, 2021, the Company received net cash proceeds of approximately $2.7 million from the exercise of stock options. During the year ended December 31, 2020, the Company received net cash proceeds of approximately $18.7 million from a debt offering, and $0.7 million from the exercise of stock options and warrants.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Principles of Consolidation The consolidated financial statements have been prepared in accordance with GAAP and include the accounts for the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited. All inter-company transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were $37.9 million, and $48.3 million at December 31, 2021 and December 31, 2020. The Company maintains cash balances at financial institutions insured up to $250,000 by the Federal Deposit Insurance Corporation ("FDIC") and as of December 31, 2021 maintains the majority of its cash balances in money market funds not insured by the FDIC. The Company also transfers certain daily available cash balances to an overnight account which earns interest and the amounts are not insured by the FDIC. Balances in the United Kingdom are insured up to £85,000 by the Financial Services Compensation Scheme (United Kingdom Equivalent). Although the Company’s cash balances exceeded these insured amounts, the Company has not experienced any losses on its cash and cash equivalents for the periods presented. Marketable Securities The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. We invest our cash primarily in U.S. Treasury securities. We consider our investments in debt securities to be "held-to-maturity," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). Realized gains and losses on held-to-maturity securities are included in other income (expense), net. The Company classifies marketable securities as current or non-current based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal operating cycle of the business. Accounts Receivable The Company routinely assesses the recoverability of receivables to determine collectability by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The Company determines its allowance for doubtful accounts by considering such factors as the length of time balances are past due, the Company’s previous loss history, the customer’s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company has evaluated its accounts receivable history and determined that no allowance for doubtful accounts is required for the years ended December 31, 2021 and 2020. At December 31, 2021 and 2020 the Company's accounts receivable were primarily concentrated with one party, EBS. Long-Lived Assets The Company follows ASC 360, Property, Plant, and Equipment , for its fixed assets. Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed by the straight-line method over estimated useful lives (3 to7 years). The Company capitalizes all asset purchases greater than $5,000 having a useful life greater than one year. The Company follows ASC 350, Intangibles – Goodwill and Other for its intellectual property asset. Intellectual property consists of patents which are stated at their fair value acquisition cost. Amortization is calculated by the straight-line method over their estimated useful lives (20 years). The Company recorded depreciation and amortization expense of $94,455 and $123,680 for the years ended December 31, 2021 and 2020, respectively. Long-lived assets such as property and equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. The Company did not recognize any impairment losses for any years presented. Earnings (Loss) per Share The Company follows ASC 260, Earnings per Share . Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying consolidated financial statements. Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). Common Stock equivalents represent the dilutive effect of the assumed exercise of outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the Common Stock equivalents are considered dilutive based upon the Company’s net income position at the calculation date. For the year ended December 31, 2021, Common Stock equivalents consisting of 302,850 stock options were excluded from the calculation of diluted income (loss) per share. The following table illustrates the dilutive effect of the assumed exercise of the Company’s outstanding stock options and warrants, using the treasury stock method, for the years ended December 31, 2021 and 2020: Year Ended Year Ended Numerator: December 31, 2021 December 31, 2020 Net Income (loss) $ 3,008,790 $ (1,861,449) Denominator: Denominator for basic income (loss) per share - weighted average shares 4,456,162 4,249,832 Effect of dilutive securities: Stock options and warrants 1,403,707 — Restricted stock units 60,200 — Convertible debt — — Denominator for diluted income (loss) per share 5,920,069 4,249,832 Income (loss) per share - Basic $ 0.68 $ (0.44) Income (loss) per share - Diluted $ 0.51 $ (0.44) Research and Development Costs The Company follows ASC 730, Research and Development , and expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation Foreign Currency Translation The Company’s functional and reporting currency is the United States dollar. The functional currency of the Company's wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited ("Opiant UK") is the British Pound, its local currency. Consequently, the assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of Opiant UK, into U.S. dollars, the reporting currency, are excluded from the determination of net loss and are recorded in accumulated other comprehensive income or loss, a separate component of equity. Gains and losses arising on settlement of foreign currency denominated transactions or balances are included in the determination of income. Stock-Based Compensation ASC 718 Compensation – Stock Compensation prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to non-employees with the guidance applicable to grants to employees. Under this new standard, equity-classified share-based payment awards issued to non-employees will be measured on the grant date, instead of the current requirement to remeasure the awards through the performance completion date. Further, compensation cost for awards with performance conditions will be recognized when it is probable the conditions will be achieved, rather than upon actual achievement of the conditions. The Company adopted this standard January 1, 2019. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements. The Company had stock-based compensation of $2.7 million and $2.3 million for the years ended December 31, 2021 and 2020, respectively. Fair Value of Financial Instruments ASC 820 Fair Value Measurements and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable, and long-term debt. The carrying value of long-term debt approximates fair value since the related rate of interest approximates current market rates. At December 31, 2021 and December 31, 2020, the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis. Revenue Recognition The Company generates a large majority of revenue from the agreement with EBS. During the year ended December 31, 2021, the Company recognized 85% of revenue from its agreement with EBS. In May 2014, the FASB issued an accounting standard update ("ASU”), 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU amends the existing accounting standards for revenue recognition and is based on the principle that revenue should be recognized to depict the transfer of goods or services to a customer at an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On January 1, 2018, the Company adopted the new Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers using the modified retrospective method, and the Company determined the new guidance does not change the Company's policy of revenue recognition. The Company's primary source of revenue is through the recognition of royalty and milestone payments from EBS. Milestone revenue is recognized upon successful accomplishment of certain sales targets set forth in the EBS Agreement. Royalty revenue is determined based on the agreed upon royalty rate applied to NARCAN® sales reported by EBS. There are no performance obligations by the Company and the Company recognizes revenue according to the royalty report provided by EBS on a quarterly basis. In regards to treatment revenue, the Company received certain investments from investors in return for an interest in its existing treatments. Investors carry an option to exchange investment into shares of the Company. Revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Once the option has expired, the Company determined its performance obligations under the agreement which typically is to perform R&D services related to treatments and recognizes revenue over a period of time which is usually the expected research and development period. The treatment revenue is disaggregated by program treatments. (See Note 8 to the Consolidated Financial Statements - Revenue). In June 2018, the FASB issued guidance clarifying the revenue recognition and measurement issues for grants, contracts, and similar arrangements, ASU Topic 958. Government grants and contracts are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company has evaluated its grant with National Institutes of Health (“NIH”) and the contract with Biomedical Advanced Research and Development Authority (“BARDA”) and determined they are non-exchange transactions and fall within the scope of ASU 958, and revenue should be recognized in accordance with Topic 958 guidance. Accordingly, the Company recognizes revenue from its grant and contract in the period during which the related costs are incurred, provided that the conditions under which the grants and contracts were provided have been met and only perfunctory performance obligations are outstanding. Licensing Agreement Pursuant to the Adapt Agreement, the Company provided a global license to develop and commercialize the Company’s intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. On December 15, 2014, the Company entered into a License Agreement (the "Adapt Agreement") with Adapt Pharma Operations Limited (“Adapt”), an Ireland based pharmaceutical company. Emergent BioSolutions, Inc acquired Adapt in October 2018 and Adapt became its wholly owned subsidiary (collectively with Adapt, “EBS”). Pursuant to the Adapt Agreement, we provided a global license to develop and commercialize our intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. In addition, in 2016 we entered into the EBS Amendment which amends the terms of the Adapt Agreement relating to the grant of a commercial sublicense outside of the United States and diligence efforts for commercialization of our Opioid Overdose Reversal Treatment Product. Under the terms of the EBS Amendment, EBS is required to use commercially reasonable efforts to commercialize the Opioid Overdose Reversal Treatment Product. In the event that EBS wishes to grant a commercial sublicense to a third party in the European Union or the United Kingdom, we have agreed to negotiate an additional amendment to the Adapt Agreement to include reduced financial terms with respect to the commercial sublicense. The Company also receives payments upon reaching various sales and regulatory milestones, as well as royalty payments for commercial sales of NARCAN® generated by EBS. During the years ended December 31, 2021 and 2020, the Company recognized royalty revenue of $40.7 million and $27.4 million, respectively. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2021, the FASB issued ASU No. 2021-10, "Government Assistance." This new standard adds disclosure requirements for the accounting of government assisted programs, including grants and contracts. The guidance requires disclosure about the nature of transactions, the related accounting policies used to account for the transactions, and the effect of the transactions on an entity’s financial statements. The Company will adopt the new standard effective January 1, 2022 and the Company determined adoption has no impact on its financial statements.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Accounts Receivable	Accounts Receivable    As of December 31, 2021, the Company had accounts receivable of $13.3 million which relates to royalty revenue from sales of NARCAN® and revenue from the contract with BARDA.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets As of December 31, 2021, the Company had approximately $3.0 million recorded as prepaid expenses and other current assets. Of this amount approximately $1.0 million was for prepaid directors and officers insurance and $2.0 million was for other prepaid insurance, rent, software services, other general prepaid items, and other current assets. As of December 31, 2020, the Company had approximately $1.9 million recorded as prepaid expenses and other current assets. Of this amount approximately $0.9 million was for prepaid directors and officers insurance and the remaining $1.0 million was for other prepaid insurance, rent, software services, and other general prepaid items.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Leases On January 1, 2019, the Company adopted a new accounting standard, Topic 842, that amends the guidance for the accounting and reporting of leases. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Company's Consolidated Balance Sheets. The Company had two operating leases during the year ended December 31, 2021. In accordance with the guidance of Topic 842, the two leases which are classified as operating leases are included in the Company's Consolidated Balance Sheet as of December 31, 2021 and 2020. The Company's two operating leases do not include options to renew, do not contain residual value guarantees, do not have variable lease components, or impose significant restrictions or covenants. Right of use assets, "ROU assets", represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments over the respective lease term, with the ROU asset adjusted for deferred rent liability. Lease expense is recognized on a straight line basis over the lease term. As the implicit rate on the leases is not determinable, the Company used an estimated incremental borrowing rate of 8.8% as the discount rate to determine the present value of lease payments. The ROU assets and corresponding operating lease liability recognized at lease inception was $1.2 million. The weighted average discount rate used was 8.8% and the weighted average remaining lease term is 4.09 years at December 31, 2021. The following table summarizes information related to the Company's two operating leases and are included in the Company's Balance Sheet as of December 31, 2021. Balance Sheet descriptions Assets: (in thousands) Right of use assets - operating leases $ 1,000 Liabilities: Operating leases - current $ 338 Operating leases - long term $ 673 Total lease liabilities $ 1,011 The following table summarizes the components of operating lease cost for the year ended December 31, 2021. Lease costs (in thousands) Operating expenses - lease costs $ 567 As of December 31, 2021, future minimum operating leases payments related to the Company’s operating lease liabilities were as follows: (in thousands) December 31, 2021 2022 352 2023 231 2024 243 2025 271 2026 112 Total lease payments 1,209 Less imputed interest $ (198) Present value of operating lease liabilities $ 1,011

Other Non-Current Assets

Other Non-Current Assets	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Non-Current Assets	Prepaid Expenses and Other Current Assets As of December 31, 2021, the Company had approximately $3.0 million recorded as prepaid expenses and other current assets. Of this amount approximately $1.0 million was for prepaid directors and officers insurance and $2.0 million was for other prepaid insurance, rent, software services, other general prepaid items, and other current assets. As of December 31, 2020, the Company had approximately $1.9 million recorded as prepaid expenses and other current assets. Of this amount approximately $0.9 million was for prepaid directors and officers insurance and the remaining $1.0 million was for other prepaid insurance, rent, software services, and other general prepaid items.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue On September 19, 2018, the Company entered into a contract with BARDA, which is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate the Company’s development of OPTN003, its lead product candidate. OPTN003, nasal nalmefene, is a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. The contract will provide potential funding up to a maximum of approximately $4.6 million and cover activities related to a potential New Drug Application submission for OPTN003 with the Food and Drug Administration. On December 11, 2020, BARDA awarded an additional $3.5 million to advance the clinical development of OPNT003. The modification increases the total potential value of the contract to $8.1 million. BARDA has awarded approximately $6.5 million of the contract through September 30, 2022, with the balance expected to be funded, subject to satisfactory project progress, availability of funds and certain other conditions. During the years ended December 31, 2021, and 2020 the Company recognized revenue of $3.7 million and $0.7 million, respectively related to this contract. Deferred revenue On April 17, 2018, the Company was awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA"). The grant provides the Company with additional resources for the ongoing development of OPNT003 (nasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. The Company has been awarded the entire grant amount of $7.4 million through the period ending March 31, 2022. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company recognizes revenues from grants in the period during which the related costs were incurred, provided that the conditions under which the grants were provided had been met and only perfunctory obligations were outstanding. During the years ended December 31, 2021 and 2020, the Company received cash of $3.0 million and $1.0 million, respectively and recognized revenue of approximately $3.3 million and $1.6 million, respectively related to this grant. The following is a summary of the Company’s deferred revenue activity for the years ended December 31, 2021 and 2020: (in thousands) NIH Grant Balance as of December 31, 2019 $ 918 Cash Received from NIH 1,000 Recognized as revenue (1,563) Balance as of December 31, 2020 $ 355 Cash Received from NIH 2,988 Recognized as revenue (3,326) Balance as of December 31, 2021 $ 17

Royalty Payable

Royalty Payable	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development its OORT Product. In exchange for this funding, the Company agreed to provide investors with interest in the OORT Net Profit generated from its OORT Product in perpetuity. The following table sets forth the royalty payable to certain investors as of December 31, 2021 and 2020: (in thousands) Net Profit % December 31, 2021 December 31, 2020 Potomac 10.2% $ 1,257 $ 822 LYL 5.0% 616 402 Welmers 1.5% 185 121 Foundation 6.0% 739 483 Pendergast 1.0% 123 80 Royalty payable 23.7% $ 2,920 $ 1,908

Long Term Debt

Long Term Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Long Term Debt	Long Term Debt On December 10, 2020 (the “Closing Date”), the Company, entered into a Note Purchase and Security Agreement (the “Loan Agreement”) with a syndicate of Pontifax Medison Finance, and Kreos Capital VI (Expert Fund) LP, (collectively, the “Lenders”). The Loan Agreement provides for term loans in an aggregate principal amount of up to $50.0 million in three tranches as follows: (a) on the Closing Date, a loan in the aggregate principal amount of $20.0 million, (b) upon the submission of a New Drug Application with the U.S. Food and Drug Administration, a loan in the aggregate principal amount of $10.0 million, and (c) upon FDA approval of an opioid overdose product, a loan in the aggregate principal amount of $20.0 million (each a “Loan, and collectively, the “Loans”). The outstanding principal of each term Loan bears an average interest rate of 8.75% per annum based on the date of issuance and a year consisting of 365 days. There is an interest-only period of 30 months, with interest on outstanding Loans payable on a quarterly basis based on the principal amount outstanding during the preceding quarter. After the interest-only period, principal of the outstanding Loans is payable in ten equal quarterly installments. All Loans have a maturity date of October 1, 2025. Each Lender may, at its option, elect to convert up to half of the then-outstanding Loans and all accrued and unpaid interest thereon into shares of Common Stock. The “Conversion Price” shall be $19.64 subject to certain customary adjustments as specified in the Loan Agreement. The Company’s obligations are secured by a security interest, senior to any current and future debts and to any security interest, in all of Company’s right, title, and interest in, to and under all of Company’s property and other assets, other than its NARCAN® Nasal Spray licensed intellectual property and other limited exceptions specified in the Loan Agreement. The Loan Agreement contains customary representations, warranties and covenants, including covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes. The Loan Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment, breaches or defaults in the performance of covenants, insolvency, bankruptcy and the occurrence of a material adverse effect on the Company. On December 10, 2020, The Company received the first tranche of $20 million. The Company recognized fees of approximately $1.3 million related to the debt offering which is amortized over the term of the debt. During the years ended December 31, 2021 and 2020 the Company amortized approximately $268 thousand and $16 thousand, respectively of these fees to interest expense.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has entered into various agreements related to its business activities. The following is a summary of the Company’s commitments: a. The Company entered into a consulting agreement with Torreya Partners LLP ("Torreya"), a financial advisory firm, under which Torreya agreed to provide certain financial advisory services. The Company is required to pay fees equivalent to 3.375% of all amounts received by the Company from net sales of NARCAN® into perpetuity. During the year ended December 31, 2021, the Company incurred approximately, $1,374,475 in aggregate fees related to Torreya. As of December 31, 2021, the Company has an accrued liability of $439,711 owed to Torreya. b. On May 7, 2019, the Company entered into a lease for office space located at 233 Wilshire Blvd., Suite 280, Santa Monica, CA 90401. The lease commenced on July 1, 2019 and effective August 1, 2021 is month-to-month. On July 11, 2019, the Company entered into an Office Service Agreement with Regus to lease office space at One Kingdom Street, London, England, W2 6BD. The lease commenced on August 1, 2019 and ends May 31, 2021 with monthly rent of 20,000 GBP. On May 21, 2021. the Company entered into a office space lease at 19-20 Berners Street, London, England. The lease commenced June 1, 2021 and ends May 31, 2026. During the years ended December 31, 2021 and 2020 Company incurred approximately $567 thousand and $578 thousand, respectively of rent expense. c. On June 22, 2017, the Company entered into a license agreement (the "License Agreement") and a related supply agreement (the “Supply Agreement”) with Aegis Therapeutics LLC ("Aegis") pursuant to which the Company was granted an exclusive license (the “License”) to Aegis’ proprietary chemically synthesizable delivery enhancement and stabilization agents, including, but not limited to, Aegis’ Intravail® absorption enhancement agents, ProTek® and HydroGel® (collectively, the “Technology”) to exploit (a) the Compounds (as such are defined in the License Agreement) and (b) a product containing a Compound and formulated using the Technology (“Aegis Product”), in each case of (a) and (b) for any and all purposes. The License Agreement restricts the Company's ability to manufacture any Aegis excipients included in the Technology (“Excipients”), except for certain instances of supply failure, supply shortage or termination of the Supply Agreement, and the Company shall obtain all supply of such Excipients from Aegis under the Supply Agreement. The License Agreement also restricts Aegis’s ability to compete with the Company worldwide with respect to the Exploitation (as defined in the License Agreement) of any therapeutic containing a Compound or derivative or active metabolite of a Compound without the Company's prior written consent. The effective date of the License Agreement and the Supply Agreement is January 1, 2017. As consideration for the grant of the License, the Company paid Aegis two immaterial upfront payments, of which the Company paid 50% by issuing Common Stock to Aegis, with the number of shares issued equal to 75% of the average closing price of the Common Stock over the 20 trading days preceding the date of payment. The License Agreement also provides for (A) additional developmental milestone payments for each Product containing a different Compound equal to up to an aggregate of $1.8 million, (B) additional commercialization milestone payments for each Aegis Product containing a different Compound equal to up to an aggregate of $5.0 million, and (C) single low digit royalties on the Annual Net Sales (as defined in the License Agreement) of all Aegis Products during the Royalty Term (as defined in the License Agreement) according to a tiered royalty rate based on Annual Net Sales of the Aegis Products by the Company, the Company's sublicensees and affiliates. The Company shall also pay to Aegis a sublicense fee based on a sublicense rate negotiated in good faith by the parties. The License Agreement contains customary representations and warranties, ownership, patent rights, confidentiality, indemnification and insurance provisions. The License Agreement shall expire upon the expiration of the Company's obligation to pay royalties under such License Agreement; provided, however, that the Company shall have the right to terminate the License granted on a product-by-product or country-by-country basis upon 30 days’ prior written notice to Aegis. Under the terms of the Supply Agreement, Aegis shall deliver to the Company any preclinical, clinical and commercial supply of the Excipients, which Aegis sources from various contract manufacturers. The Supply Agreement has a term of 20 years but shall terminate automatically in the event of expiration or termination of the License Agreement or at any time upon the written agreement of both parties. The Supply Agreement contains customary provisions relating to pricing for such materials, forecasts, delivery, inspection, indemnification, insurance and representations, warranties and covenants. The Supply Agreement includes technology transfer provisions for the transfer of all materials and know-how specific to the manufacturing of the Excipients that is necessary or useful for the Company to manufacture such Excipients. The Company does not have the right to manufacture such Excipients except in the event that Aegis is unable to supply and sell any portion of the material to the Company (subject to a 60-day cure period). Under the License Agreement, the Company will be required to pay Aegis $250,000 upon the successful filing of an NDA. For the years ended December 31, 2021 and 2020, the Company recorded $0 of milestone or royalty expense associated with the License Agreement. d. On July 22, 2020, the Company entered into a Project Scope Agreement ("PSA") pursuant to a Master Services Agreement ("MSA") with Summit Biosciences, Inc. ("Summit"), to support the development and manufacture of a nasal spray device for opioid overdose, with the ability to expand to additional programs in the future. In accordance with the PSA, Summit will develop and produce certain pre-filled nasal spray products using a device previously evaluated as part of other FDA-approved nasal spray products. The Company will pay Summit estimated costs and fees up to approximately $7.9 million. The Company paid a deposit of approximately $1.1 million which is included in prepaid expenses and other currents assets in the consolidated balance sheet at December 31, 2021, and other non-current assets in the consolidated balance sheet at December 31, 2020. e. On October 26, 2020, the Company entered into a Master Services Agreement (“MSA”) with AptarGroup, Inc. (“Aptar”) to provide non-exclusive technology access and co-development services for the development and submission of an opioid antagonist for the treatment of opioid overdose using Aptar’s nasal Unidose device (the “UDS Device”). In addition to the cost of the UDS Devices, the Company expects to spend up to approximately $5.2 million over the course of the development program. During 2021 the Company paid Aptar approximately $0.9 million. Contingencies The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. If any legal matter, that may arise, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial statements for that reporting period. The Company and EBS (collectively, “Plaintiffs”), filed complaints, in 2016 against Teva Pharmaceuticals Industries Ltd. (“Teva”) and in 2018 against Perrigo UK FINCO Limited Partnership (“Perrigo”), relating to Teva’s and Perrigo’s respective abbreviated new drug applications (each, an “ANDA”) seeking to market generic versions of NARCAN® (naloxone hydrochloride) Nasal Spray 4mg/spray. On January 21, 2022, the Plaintiffs and Teva Canada Limited entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Teva Canada can launch a generic NARCAN® after December 15, 2023. This date can be accelerated if a third party receives approval from the Canadian Food Inspection Agency sooner. On February 12, 2020, Plaintiffs and Perrigo entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Perrigo has received a non-exclusive license under the Company's patents licensed to EBS to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo’s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva or litigation against future ANDA filers. The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey. Closing arguments in the Teva trial were held on February 26, 2020. On June 5, 2020, the District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of Teva. Our commercial partner EBS, appealed the decision to the Court of Appeals for the Federal Circuit. On February 10, 2022, the Court of Appeals for the Federal Circuit upheld the District court decision.

Stockholder's Equity

Stockholder's Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholder's Equity Common Stock During the year ended December 31, 2021 Common Stock During the year ended December 31, 2021 the Company issued 448,847 shares of Common Stock as a result of employee stock option exercises, and received net cash proceeds of approximately $2.7 million. During the year ended December 31, 2021 the Company issued 19,902 shares of Common Stock as a result of vesting of employee restricted stock. During the year ended December 31, 2021 the Company issued 155,916 shares of Common Stock as a result of conversion of debt to equity at a conversion price of $19.64 per share. During the year ended December 31, 2021, the Company issued 27,076 shares of its Common Stock in relation to the cashless exercise of stock options that were granted outside of the Company's 2017 Long-Term Incentive Stock Plan (the "2017 Plan"). A total of 35,000 stock options were exercised at an exercise price of $7.25 per share. During the year ended December 31, 2020 Common Stock During the year ended December 31, 2020 the Company issued 71,667 shares of Common Stock as a result of employee stock option and warrant exercises, and received net cash proceeds of approximately $0.7 million. Equity Plans On September 8, 2017, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”), at which time the 2017 Plan was approved by stockholder vote. The 2017 Plan allows the Company to grant incentive stock options (“ISOs”), non-qualified stock options (“NSOs”), and restricted stock units ("RSU's") to purchase a maximum of 400,000 shares of the Company's Common Stock. Under the terms of the 2017 Plan, ISOs and restricted stock units may only be granted to Company employees and directors, while NSOs may be granted to employees, directors, advisors, and consultants. The Board has the authority to determine to whom options and will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value for an ISO or an NSO. The vesting period is normally over a period of four years from the vesting date. The contractual term of an option is no longer than ten years. As provided in the 2017 Plan, on January 1, 2021, the number of shares available for issuance was increased by 4% of the Company's outstanding stock as of December 31, 2020, which represents an increase of 170,324 shares. As of December 31, 2021, the Company had 104,255 shares available for future issuance under the 2017 Plan. Prior to adopting the 2017 Plan, the Company did not have a formal long-term incentive stock plan. Prior to the implementation of the 2017 Plan, the Company had discretion to provide designated employees of the Company and its affiliates, certain consultants, and advisors who perform services for the Company and its affiliates, and non-employee members of the Board and its affiliates with the opportunity to receive grants of non-qualified stock options (the "Pre-2017 Non-Qualified Stock Options"). All of the Pre-2017 Non-Qualified Stock Option Grants were intended to qualify as non-qualified stock options. There were no Pre-2017 Non-Qualified Stock Option Grants that were intended to qualify as incentive stock options. On July 8, 2021, the Board of Directors of the Company adopted the 2021 Inducement Equity Incentive Plan (the “Inducement Plan”) and, subject to the adjustment provisions of the Inducement Plan, reserved 100,000 shares of the Company’s Common Stock for issuance pursuant to equity awards granted under the Inducement Plan. On December 9, 2021, the Board of Directors of the Company amended the Inducement Plan to reserve an additional 100,000 shares of the Company’s Common Stock. Stock option activity for the Pre-2017 Non-Qualified Stock Options for the years ended December 31, 2021 and 2020, is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 2,500,500 $ 7.03 5.05 $ 18,426,325 Exercised (20,000) $ 9.50 Forfeited (15,000) $ 10.00 Outstanding at December 31, 2020 2,465,500 $ 6.99 4.09 $ 2,773,190 Exercised (480,002) $ 5.86 Forfeited (34,998) $ 10.00 Outstanding at December 31, 2021 1,950,500 $ 7.17 3.4 $ 51,602,190 Exercisable at December 31, 2021 1,950,500 $ 7.17 3.4 $ 51,602,190 During the years ended December 31, 2021 and 2020, the Company recognized $0 and $1,235 of non-cash expense related to vested Pre-2017 Non-Qualified Stock Options granted in prior periods. The 2017 Plan The assumptions used in the valuation of options granted under the 2017 Plan during the years ended December 31, 2021 and 2020 were as follows: Year Ended December 31, 2021 Year Ended December 31, 2020 Market value of stock on measurement date $8.20 to $24.75 $8.79 to $13.60 Risk-free interest rate 0.50% to 1.30% 0.33% to 1.68% Dividend yield — % — % Volatility factor 76% to 89% 91% to 101% Term (years) 5.5 to 6.25 5.5 to 6.25 Stock option activity for options granted under the 2017 Plan during the years ended December 31, 2021 and 2020 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 491,950 $ 24.08 8.43 $ 81,888 Granted 191,500 $ 12.12 Exercised — — Forfeited (71,690) $ 15.05 Outstanding at December 31, 2020 611,760 $ 21.39 7.85 $ — Granted 163,285 $ 12.4 Exercised (3,845) $ 19.49 Forfeited (12,142) $ 12.60 Balance at December 31, 2021 759,058 $ 19.61 7.31 $ 10,997,428 Exercisable at December 31, 2021 513,279 $ 22.84 6.72 $ 5,895,856 During the years ended December 31, 2021 and 2020, the Company recognized approximately $1.7 million and $2.1 million of non-cash expense related to vested options granted during these periods. As of December 31, 2021, there was approximately $1.0 million of unrecognized compensation costs related to non-vested stock options that were granted under the 2017 Plan. Restricted Stock Units Restricted stock activity during the year ended December 31, 2021 is presented in the following table. Number of Shares Grant Date Fair Value Per Share Restricted stock units outstanding December 31, 2019 27,000 $14.51 Restricted stock granted 49,600 $12.00 Restricted stock forfeited (27,000) $14.51 Restricted stock units outstanding December 31, 2020 49,600 $12.00 Restricted stock granted 76,268 $12.47 Restricted stock vested (19,902) $10.79 Restricted stock forfeited (1,550) $12.15 Restricted stock units outstanding December 31, 2021 104,416 $12.57 Twenty-five percent (25%) of the restricted stock units will vest on the one year anniversary of the vesting commencement date, and twenty-five percent (25%) will vest annually thereafter on the same day as the vesting commencement date. During the year ended December 31, 2021 and 2020, the Company recognized approximately $0.8 million and $0.2 million of non-cash expense related to restricted stock units. As of December 31, 2021, there was $0.5 million of total unrecognized compensation cost related to restricted stock units. Inducement Equity Incentive Plan During 2021, the Company granted options to purchase 56,500 shares of Common Stock, and granted RSUs for 49,800 shares of Common Stock under the Inducement Plan. The assumptions used in the valuation of options granted under the Inducement Plan during the year ended December 31, 2021 were as follows: Year Ended December 31, 2021 Market value of stock on measurement date $ 16.41 Risk-free interest rate 0.84 % Dividend yield — % Volatility factor 76.26 % Term (years) 6.25 Stock option activity for options granted under the Inducement Plan during the year ended December 31, 2021 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance at December 31, 2020 — Granted 56,500 $ 16.41 Exercised — Forfeited — Balance at December 31, 2021 56,500 $ 16.41 9.55 $ 972,930 During the year ended December 31, 2021, the Company recognized approximately $0.2 million of non-cash expense related to options granted under the Inducement Plan. As of December 31, 2021, there was approximately $0.4 million of total unrecognized compensation cost related to the non-vested stock options that were granted under the 2021 Inducement Equity Incentive Plan. The following summarizes the restricted stock activity under the Inducement Plan during the year ended December 31, 2021: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2020 — Restricted stock granted 49,800 $ 26.98 Restricted stock vested Restricted stock outstanding and unvested at December 31, 2021 49,800 $ 26.98 During the year ended December 31, 2021, the Company recognized approximately $0.1 million of non-cash expense related to restricted stock units. As of December 31, 2021, there was approximately $1.2 million of total unrecognized compensation cost related to restricted stock units. Warrants Warrant activity for the years ended December 31, 2021 and 2020 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 342,610 $ 9.77 3.71 $ 1,585,084 Exercised (59,510) $ 10.00 Forfeited (4,300) $ 10.00 Outstanding at December 31, 2020 278,800 $ 9.72 3.51 $ 1,164 Exercised — $ — Forfeited — $ — Outstanding at December 31, 2021 278,800 $ 9.72 2.51 $ 6,665,644 Exercisable at December 31, 2021 278,800 $ 9.72 2.51 $ 6,665,644

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities using the asset and liability method. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. This method requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2021, the Company’s deferred tax assets primarily relate to net operating loss (“NOL”) carryforwards that were derived from operating losses and stock based compensation from prior years. A full valuation allowance has been applied to the Company’s deferred tax assets. The valuation allowance will be reduced when and if the Company determines it is more likely than not that the related deferred income tax assets will be realized. At December 31, 2021, the Company had federal net operating loss carry forwards, which are available to offset future taxable income, of $7,273,220. The Company’s NOL carryforwards generated prior to January 1, 2018 of $3,192,777 can be carried forward to offset future taxable income for a period of 20 years for each tax year’s loss. These NOL carryforwards begin to expire in 2035. No provision was made for federal income taxes as the Company has NOLs. The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate to the net loss before provision for income taxes for the following reasons: December 31, 2021 December 31, 2020 Net loss before taxes at statutory rate $ 860,542 $ (352,562) Permanent items (575,449) 479,115 Temporary items (420,274) 312,649 Income tax expense at statutory rate (135,181) 439,202 Valuation allowance 159,451 (864,881) Income tax expense (benefit) per books $ 24,270 $ (425,679) Net deferred tax assets consist of the following components as of: December 31, 2021 December 31, 2020 Net operating loss carryover at statutory rate $ 4,497,897 $ 3,881,105 Stock-based compensation expense 3,544,938 2,923,099 Fixed asset depreciation (18,378) (38,863) Intangibles amortization (1,134) (1,081) Other 3,391 307,044 Total $ 8,026,714 $ 7,071,304 Valuation allowance $ (8,026,714) $ (7,071,304) Net deferred tax asset $ — $ — The Company had no uncertain tax positions at December 31, 2021 and December 31, 2020. The Company is subject to income taxation by the United States government and certain states in which the Company's activities give rise to an income tax filing requirement. The Company does not have any significant income tax filing requirements in any foreign jurisdiction. As of December 31, 2021, there were no pending tax audits in any jurisdiction. The tax returns are subject to statutes of limitations that vary by jurisdiction. At December 31, 2021, the Company remains subject to income tax examinations in the U.S. and various states for tax years 2018 through 2021; certain other states remain subject to examination for tax years 2017 through 2021. However, due to the Company’s NOL carryforwards in various jurisdictions, tax authorities have the ability to adjust carryforwards related to closed years until the statute expires on the year(s) in which the NOL carryforwards are utilized.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company has signed a new lease at 233 Wilshire Blvd., Suite 400 Santa Monica, CA. The lease is for 5 years and this is the new corporate address. On January 4, 2022, the Company issued restricted stock units ("RSUs") to employees for 135,475 shares of Common Stock. The price of the Common Stock on the date of issuance was $32.85 per share. The RSUs were issued under the 2017 Plan. The RSUs vest 1/3 each year for the next three years on the anniversary of the grant date. On January 4, 2022, the Company issued performance stock units ("PSUs") to certain employees for 80,735 shares of Common Stock. The price of the Common Stock on the date of issuance was $32.85 per share. The PSUs were issued under the 2017 Plan. The PSUs vest equally at 25% upon the achievement of various performance milestones. On January 24, 2022, the Company announced a modification to its contract with BARDA for an additional commitment of up to $2.2 million to support OPNT003, nasal nalmefene, for opioid overdose. The increase in funding is primarily directed toward the costs of the Company's clinical studies to support its submission of OPNT003 to the FDA. During Q1 2022, Pontifa x Medisen Finance ("Pontifax") voluntarily converted approximately $1.4 million of the outstanding $7.9 million convertible debt held by Pontifax into a total of 70,000 shares of common stock at a conversion rate of $19.64 per share. In addition, Kreos Capital ("Kreos") voluntarily converted approximately $1 million of the outstanding $9 million convertible debt held by Kreos into a total of 50,916 shares of common stock at a conversion rate of $19.64 per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”).
Principles of Consolidation	The consolidated financial statements have been prepared in accordance with GAAP and include the accounts for the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited. All inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were $37.9 million, and $48.3 million at December 31, 2021 and December 31, 2020. The Company maintains cash balances at financial institutions insured up to $250,000 by the Federal Deposit Insurance Corporation ("FDIC") and as of December 31, 2021 maintains the majority of its cash balances in money market funds not insured by the FDIC. The Company also transfers certain daily available cash balances to an overnight account which earns interest and the amounts are not insured by the FDIC. Balances in the United Kingdom are insured up to £85,000 by the Financial Services Compensation Scheme (United Kingdom Equivalent). Although the Company’s cash balances exceeded these insured amounts, the Company has not experienced any losses on its cash and cash equivalents for the periods presented.
Marketable Securities	The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and diversification. We invest our cash primarily in U.S. Treasury securities. We consider our investments in debt securities to be "held-to-maturity," as defined by authoritative guidance issued by the Financial Accounting Standards Board ("FASB"). Realized gains and losses on held-to-maturity securities are included in other income (expense), net. The Company classifies marketable securities as current or non-current based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal operating cycle of the business.
Accounts Receivable	The Company routinely assesses the recoverability of receivables to determine collectability by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The Company determines its allowance for doubtful accounts by considering such factors as the length of time balances are past due, the Company’s previous loss history, the customer’s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole.The Company has evaluated its accounts receivable history and determined that no allowance for doubtful accounts is required for the years ended December 31, 2021 and 2020. At December 31, 2021 and 2020 the Company's accounts receivable were primarily concentrated with one party, EBS.
Long-Lived Assets	The Company follows ASC 360, Property, Plant, and Equipment , for its fixed assets. Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed by the straight-line method over estimated useful lives (3 to7 years). The Company capitalizes all asset purchases greater than $5,000 having a useful life greater than one year. The Company follows ASC 350, Intangibles – Goodwill and Other for its intellectual property asset. Intellectual property consists of patents which are stated at their fair value acquisition cost. Amortization is calculated by the straight-line method over their estimated useful lives (20 years). The Company recorded depreciation and amortization expense of $94,455 and $123,680 for the years ended December 31, 2021 and 2020, respectively. Long-lived assets such as property and equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. The Company did not recognize any impairment losses for any years presented.
Earnings (Loss) per Share	The Company follows ASC 260, Earnings per Share . Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying consolidated financial statements. Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). Common Stock equivalents represent the dilutive effect of the assumed exercise of outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the Common Stock equivalents are considered dilutive based upon the Company’s net income position at the calculation date.
Research and Development Costs	The Company follows ASC 730, Research and Development , and expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation
Foreign Currency Translation	The Company’s functional and reporting currency is the United States dollar. The functional currency of the Company's wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited ("Opiant UK") is the British Pound, its local currency. Consequently, the assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of Opiant UK, into U.S. dollars, the reporting currency, are excluded from the determination of net loss and are recorded in accumulated other comprehensive income or loss, a separate component of equity. Gains and losses arising on settlement of foreign currency denominated transactions or balances are included in the determination of income.
Stock-Based Compensation	ASC 718 Compensation – Stock Compensation prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to non-employees with the guidance applicable to grants to employees. Under this new standard, equity-classified share-based payment awards issued to non-employees will be measured on the grant date, instead of the current requirement to remeasure the awards through the performance completion date. Further, compensation cost for awards with performance conditions will be recognized when it is probable the conditions will be achieved, rather than upon actual achievement of the conditions. The Company adopted this standard January 1, 2019. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
Fair Value of Financial Instruments	ASC 820 Fair Value Measurements and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable, and long-term debt. The carrying value of long-term debt approximates fair value since the related rate of interest approximates current market rates.
Revenue Recognition	The Company generates a large majority of revenue from the agreement with EBS. During the year ended December 31, 2021, the Company recognized 85% of revenue from its agreement with EBS. In May 2014, the FASB issued an accounting standard update ("ASU”), 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU amends the existing accounting standards for revenue recognition and is based on the principle that revenue should be recognized to depict the transfer of goods or services to a customer at an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On January 1, 2018, the Company adopted the new Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers using the modified retrospective method, and the Company determined the new guidance does not change the Company's policy of revenue recognition. The Company's primary source of revenue is through the recognition of royalty and milestone payments from EBS. Milestone revenue is recognized upon successful accomplishment of certain sales targets set forth in the EBS Agreement. Royalty revenue is determined based on the agreed upon royalty rate applied to NARCAN® sales reported by EBS. There are no performance obligations by the Company and the Company recognizes revenue according to the royalty report provided by EBS on a quarterly basis. In regards to treatment revenue, the Company received certain investments from investors in return for an interest in its existing treatments. Investors carry an option to exchange investment into shares of the Company. Revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Once the option has expired, the Company determined its performance obligations under the agreement which typically is to perform R&D services related to treatments and recognizes revenue over a period of time which is usually the expected research and development period. The treatment revenue is disaggregated by program treatments. (See Note 8 to the Consolidated Financial Statements - Revenue). In June 2018, the FASB issued guidance clarifying the revenue recognition and measurement issues for grants, contracts, and similar arrangements, ASU Topic 958. Government grants and contracts are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company has evaluated its grant with National Institutes of Health (“NIH”) and the contract with Biomedical Advanced Research and Development Authority (“BARDA”) and determined they are non-exchange transactions and fall within the scope of ASU 958, and revenue should be recognized in accordance with Topic 958 guidance. Accordingly, the Company recognizes revenue from its grant and contract in the period during which the related costs are incurred, provided that the conditions under which the grants and contracts were provided have been met and only perfunctory performance obligations are outstanding. Licensing Agreement Pursuant to the Adapt Agreement, the Company provided a global license to develop and commercialize the Company’s intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. On December 15, 2014, the Company entered into a License Agreement (the "Adapt Agreement") with Adapt Pharma Operations Limited (“Adapt”), an Ireland based pharmaceutical company. Emergent BioSolutions, Inc acquired Adapt in October 2018 and Adapt became its wholly owned subsidiary (collectively with Adapt, “EBS”). Pursuant to the Adapt Agreement, we provided a global license to develop and commercialize our intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. In addition, in 2016 we entered into the EBS Amendment which amends the terms of the Adapt Agreement relating to the grant of a commercial sublicense outside of the United States and diligence efforts for commercialization of our Opioid Overdose Reversal Treatment Product. Under the terms of the EBS Amendment, EBS is required to use commercially reasonable efforts to commercialize the Opioid Overdose Reversal Treatment Product. In the event that EBS wishes to grant a commercial sublicense to a third party in the European Union or the United Kingdom, we have agreed to negotiate an additional amendment to the Adapt Agreement to include reduced financial terms with respect to the commercial sublicense.
Recently Issued Accounting Pronouncements	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2021, the FASB issued ASU No. 2021-10, "Government Assistance." This new standard adds disclosure requirements for the accounting of government assisted programs, including grants and contracts. The guidance requires disclosure about the nature of transactions, the related accounting policies used to account for the transactions, and the effect of the transactions on an entity’s financial statements. The Company will adopt the new standard effective January 1, 2022 and the Company determined adoption has no impact on its financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table illustrates the dilutive effect of the assumed exercise of the Company’s outstanding stock options and warrants, using the treasury stock method, for the years ended December 31, 2021 and 2020: Year Ended Year Ended Numerator: December 31, 2021 December 31, 2020 Net Income (loss) $ 3,008,790 $ (1,861,449) Denominator: Denominator for basic income (loss) per share - weighted average shares 4,456,162 4,249,832 Effect of dilutive securities: Stock options and warrants 1,403,707 — Restricted stock units 60,200 — Convertible debt — — Denominator for diluted income (loss) per share 5,920,069 4,249,832 Income (loss) per share - Basic $ 0.68 $ (0.44) Income (loss) per share - Diluted $ 0.51 $ (0.44)

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Summary of Operating Leases	The following table summarizes information related to the Company's two operating leases and are included in the Company's Balance Sheet as of December 31, 2021. Balance Sheet descriptions Assets: (in thousands) Right of use assets - operating leases $ 1,000 Liabilities: Operating leases - current $ 338 Operating leases - long term $ 673 Total lease liabilities $ 1,011
Summary of Components of Operating Lease Cost	The following table summarizes the components of operating lease cost for the year ended December 31, 2021. Lease costs (in thousands) Operating expenses - lease costs $ 567
Schedule of Maturity of Operating Lease Liabilities	As of December 31, 2021, future minimum operating leases payments related to the Company’s operating lease liabilities were as follows: (in thousands) December 31, 2021 2022 352 2023 231 2024 243 2025 271 2026 112 Total lease payments 1,209 Less imputed interest $ (198) Present value of operating lease liabilities $ 1,011

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Deferred Revenue	The following is a summary of the Company’s deferred revenue activity for the years ended December 31, 2021 and 2020: (in thousands) NIH Grant Balance as of December 31, 2019 $ 918 Cash Received from NIH 1,000 Recognized as revenue (1,563) Balance as of December 31, 2020 $ 355 Cash Received from NIH 2,988 Recognized as revenue (3,326) Balance as of December 31, 2021 $ 17

Royalty Payable (Tables)

Royalty Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Royalty Payable	The following table sets forth the royalty payable to certain investors as of December 31, 2021 and 2020: (in thousands) Net Profit % December 31, 2021 December 31, 2020 Potomac 10.2% $ 1,257 $ 822 LYL 5.0% 616 402 Welmers 1.5% 185 121 Foundation 6.0% 739 483 Pendergast 1.0% 123 80 Royalty payable 23.7% $ 2,920 $ 1,908

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	Stock option activity for the Pre-2017 Non-Qualified Stock Options for the years ended December 31, 2021 and 2020, is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 2,500,500 $ 7.03 5.05 $ 18,426,325 Exercised (20,000) $ 9.50 Forfeited (15,000) $ 10.00 Outstanding at December 31, 2020 2,465,500 $ 6.99 4.09 $ 2,773,190 Exercised (480,002) $ 5.86 Forfeited (34,998) $ 10.00 Outstanding at December 31, 2021 1,950,500 $ 7.17 3.4 $ 51,602,190 Exercisable at December 31, 2021 1,950,500 $ 7.17 3.4 $ 51,602,190 Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 491,950 $ 24.08 8.43 $ 81,888 Granted 191,500 $ 12.12 Exercised — — Forfeited (71,690) $ 15.05 Outstanding at December 31, 2020 611,760 $ 21.39 7.85 $ — Granted 163,285 $ 12.4 Exercised (3,845) $ 19.49 Forfeited (12,142) $ 12.60 Balance at December 31, 2021 759,058 $ 19.61 7.31 $ 10,997,428 Exercisable at December 31, 2021 513,279 $ 22.84 6.72 $ 5,895,856 Stock option activity for options granted under the Inducement Plan during the year ended December 31, 2021 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance at December 31, 2020 — Granted 56,500 $ 16.41 Exercised — Forfeited — Balance at December 31, 2021 56,500 $ 16.41 9.55 $ 972,930
Schedule of Assumptions Used in the Valuation	The assumptions used in the valuation of options granted under the 2017 Plan during the years ended December 31, 2021 and 2020 were as follows: Year Ended December 31, 2021 Year Ended December 31, 2020 Market value of stock on measurement date $8.20 to $24.75 $8.79 to $13.60 Risk-free interest rate 0.50% to 1.30% 0.33% to 1.68% Dividend yield — % — % Volatility factor 76% to 89% 91% to 101% Term (years) 5.5 to 6.25 5.5 to 6.25 Year Ended December 31, 2021 Market value of stock on measurement date $ 16.41 Risk-free interest rate 0.84 % Dividend yield — % Volatility factor 76.26 % Term (years) 6.25
Schedule of Nonvested Restricted Stock Units Activity	Restricted stock activity during the year ended December 31, 2021 is presented in the following table. Number of Shares Grant Date Fair Value Per Share Restricted stock units outstanding December 31, 2019 27,000 $14.51 Restricted stock granted 49,600 $12.00 Restricted stock forfeited (27,000) $14.51 Restricted stock units outstanding December 31, 2020 49,600 $12.00 Restricted stock granted 76,268 $12.47 Restricted stock vested (19,902) $10.79 Restricted stock forfeited (1,550) $12.15 Restricted stock units outstanding December 31, 2021 104,416 $12.57
Schedule of Nonvested Restricted Stock Shares Activity	The following summarizes the restricted stock activity under the Inducement Plan during the year ended December 31, 2021: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2020 — Restricted stock granted 49,800 $ 26.98 Restricted stock vested Restricted stock outstanding and unvested at December 31, 2021 49,800 $ 26.98
Schedule of Share-based Compensation, Warrant Activity	Warrant activity for the years ended December 31, 2021 and 2020 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2019 342,610 $ 9.77 3.71 $ 1,585,084 Exercised (59,510) $ 10.00 Forfeited (4,300) $ 10.00 Outstanding at December 31, 2020 278,800 $ 9.72 3.51 $ 1,164 Exercised — $ — Forfeited — $ — Outstanding at December 31, 2021 278,800 $ 9.72 2.51 $ 6,665,644 Exercisable at December 31, 2021 278,800 $ 9.72 2.51 $ 6,665,644

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate to the net loss before provision for income taxes for the following reasons: December 31, 2021 December 31, 2020 Net loss before taxes at statutory rate $ 860,542 $ (352,562) Permanent items (575,449) 479,115 Temporary items (420,274) 312,649 Income tax expense at statutory rate (135,181) 439,202 Valuation allowance 159,451 (864,881) Income tax expense (benefit) per books $ 24,270 $ (425,679)
Schedule of Deferred Tax Assets and Liabilities	Net deferred tax assets consist of the following components as of: December 31, 2021 December 31, 2020 Net operating loss carryover at statutory rate $ 4,497,897 $ 3,881,105 Stock-based compensation expense 3,544,938 2,923,099 Fixed asset depreciation (18,378) (38,863) Intangibles amortization (1,134) (1,081) Other 3,391 307,044 Total $ 8,026,714 $ 7,071,304 Valuation allowance $ (8,026,714) $ (7,071,304) Net deferred tax asset $ — $ —

Liquidity and Financial Condi_2

Liquidity and Financial Condition (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income (loss)	$ 3,008,790	$ (1,861,449)
Accumulated deficit	61,680,275	64,689,065
Working capital	62,300,000
Proceeds from stock options exercised	2,700,000	2,700,000
Proceeds from debt offering		18,700,000
Proceeds from exercise of options and warrants	$ 2,718,940	$ 685,100

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 37,853,947		$ 48,251,336
Cash balances at financial institutions	$ 250,000
United Kingdom
Cash and Cash Equivalents [Line Items]
Cash balances at financial institutions | €		€ 85,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 0	$ 0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Long-Lived Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Capitalized asset purchase price (greater than)	$ 5,000
Finite-lived intangible asset, useful life	20 years
Depreciation and amortization	$ 94,455	$ 123,680
Impairment of long-lived assets	$ 0	$ 0
Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Earnings (Loss) Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Basic:
Net Income (loss)	$ 3,008,790	$ (1,861,449)
Denominator:
Denominator for basic income (loss) per share - weighted average shares (in shares)	4,456,162	4,249,832
Effect of dilutive securities
Convertible Debt (in shares)	0	0
Denominator for diluted income (loss) per share (in shares)	5,920,069	4,249,832
Income (loss) per share - Basic (in dollars per share)	$ 0.68	$ (0.44)
Income (loss) per share - Diluted (in dollars per share)	$ 0.51	$ (0.44)
Stock options and warrants
Effect of dilutive securities
Share based (in shares)	1,403,707	0
Restricted stock units
Effect of dilutive securities
Share based (in shares)	60,200	0
Employee Stock Option
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities (in shares)	302,850

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Share-based compensation	$ 2,748,300	$ 2,279,496

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities, fair value	$ 0	$ 0

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Royalty and licensing revenue	$ 40,725,185	$ 27,401,919
Revenue Benchmark | Adapt Agreement | Revenue from Rights Concentration Risk
Disaggregation of Revenue [Line Items]
Percent of revenue recognized	85.00%

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 13,327,364	$ 8,910,975
Royalty Revenue from Sales of NARCAN
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 13,300,000

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Long-term Purchase Commitment [Line Items]
Prepaid expenses and other current assets	$ 2,962,903	$ 1,936,842
Prepaid expense	2,000,000	1,000,000
Research and Development Arrangement
Long-term Purchase Commitment [Line Items]
Payments to acquire in-process research and development	$ 1,000,000	$ 900,000

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)lease	Dec. 31, 2020lease	Jan. 01, 2019USD ($)
Leases [Abstract]
Number operating leases | lease	2	2
Estimated incremental borrowing rate	8.80%
Present value of operating lease liabilities | $	$ 1,011		$ 1,200
Operating lease, weighted average discount rate, percent	8.80%
Operating lease, weighted average remaining lease term	4 years 1 month 2 days

Leases - Balance Sheet Descript

Leases - Balance Sheet Descriptions of Operating Leases (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2019
Assets:
Right of use assets - operating leases	$ 999,567	$ 278,455
Liabilities:
Operating leases - current	337,690	282,421
Operating leases - long term	673,347	$ 0
Total lease liabilities	$ 1,011,000		$ 1,200,000

Leases - Components of Operatin

Leases - Components of Operating Lease Cost (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Leases [Abstract]
Operating expenses - lease costs	$ 567

Leases - Maturity of Operating

Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 01, 2019
Leases [Abstract]
2022	$ 352
2023	231
2024	243
2025	271
2026	112
Total lease payments	1,209
Less imputed interest	(198)
Present value of operating lease liabilities	$ 1,011	$ 1,200

Other Non-Current Assets - Narr

Other Non-Current Assets - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non-current assets	$ 0.2	$ 1.1

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($)	Dec. 11, 2020	Sep. 19, 2018	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Sep. 30, 2022	Apr. 17, 2018
Disaggregation of Revenue [Line Items]
Royalty revenue			$ 40,725,185	$ 27,401,919
Grants receivable							$ 7,400,000
Deferred revenue, period increase (decrease)			3,000,000	1,000,000
Grant
Disaggregation of Revenue [Line Items]
Royalty revenue			3,300,000	1,600,000
Research And Development Arrangement September 19, 2018
Disaggregation of Revenue [Line Items]
Royalty revenue			$ 3,700,000	$ 700,000
Scenario, Forecast | Grant
Disaggregation of Revenue [Line Items]
Royalty revenue					$ 7,400,000
Biomedical Advanced Research and Development Authority (BARDA)
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement	$ 3,500,000	$ 4,600,000
Biomedical Advanced Research and Development Authority (BARDA) | Plan
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement		$ 8,100,000
Biomedical Advanced Research and Development Authority (BARDA) | Scenario, Forecast
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement						$ 6,500,000

Revenue - Summary of Deferred R

Revenue - Summary of Deferred Revenue Activity (Details) - NIH Grant - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	$ 355	$ 918
Cash Received from NIH	2,988	1,000
Recognized as revenue	(3,326)	(1,563)
Balance at end of period	$ 17	$ 355

Royalty Payable (Details)

Royalty Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of Royalties [Line Items]
Net Profit %	23.70%
Royalty payable	$ 2,920	$ 1,908
Potomac
Schedule of Royalties [Line Items]
Net Profit %	10.20%
Royalty payable	$ 1,257	822
LYL
Schedule of Royalties [Line Items]
Net Profit %	5.00%
Royalty payable	$ 616	402
Welmers
Schedule of Royalties [Line Items]
Net Profit %	1.50%
Royalty payable	$ 185	121
Foundation
Schedule of Royalties [Line Items]
Net Profit %	6.00%
Royalty payable	$ 739	483
Pendergast
Schedule of Royalties [Line Items]
Net Profit %	1.00%
Royalty payable	$ 123	$ 80

Long Term Debt (Details)

Long Term Debt (Details) - Loan Agreement	Dec. 10, 2020USD ($)tranche$ / shares	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Line of Credit Facility [Line Items]
Aggregate principal amount	$ 50,000,000
Number of tranche | tranche	3
Average interest rate	8.75%
Interest on outstanding loans	30 months
Conversion price par value (in dollars per share) | $ / shares	$ 19.64
Debt fees	$ 1,300,000
Amortization of debt fees		$ 268,000	$ 16,000
Debt conversion, original debt, amount		3,100,000
Unamortized debt discount		$ 163,000
Tranche One
Line of Credit Facility [Line Items]
Aggregate principal amount	20,000,000
Amount received the first tranche	20,000,000
Tranche Two
Line of Credit Facility [Line Items]
Aggregate principal amount	10,000,000
Tranche Three
Line of Credit Facility [Line Items]
Aggregate principal amount	$ 20,000,000

Commitments and Contingencies -

Commitments and Contingencies - 2014 Agreement (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Commitments [Line Items]
Pay fees equivalent	3.375%
Accrued liabilities	$ 439,711
Summit BioScience, Inc.
Other Commitments [Line Items]
Deposit payment	1,100,000	$ 1,100,000
Torreya
Other Commitments [Line Items]
Advisory fees	$ 1,374,475

Commitments and Contingencies_2

Commitments and Contingencies - Sublease Agreement (Details) $ in Thousands	Jul. 22, 2020USD ($)	Jul. 11, 2019GBP (£)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Other Commitments [Line Items]
Rent expense | £		£ 20,000
Standish Management, LLC
Other Commitments [Line Items]
Rent expense			$ 567	$ 578
Summit BioScience, Inc.
Other Commitments [Line Items]
Agreement expense	$ 7,900

Commitments and Contingencies_3

Commitments and Contingencies - License Agreement (Details)	Oct. 26, 2020USD ($)	Jun. 22, 2017USD ($)paymenttrading_day	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Other Commitments [Line Items]
License agreement cost		$ 250,000
Royalty expenses			$ 9,066,432	$ 6,196,706
Development program cost	$ 5,200,000
Payment for development costs			900,000
Severance costs				1,200,000
License Agreement
Other Commitments [Line Items]
Upfront payments | payment		2
Percent of upfront payments which may be paid by issuing common stock		50.00%
Percent of average share price		75.00%
Threshold trading days | trading_day		20
Maximum additional product milestone payments		$ 1,800,000
Maximum additional commercialization milestone payments		$ 5,000,000
Termination advance notice period		30 days
Royalty expenses			$ 0	$ 0
Supply Agreement
Other Commitments [Line Items]
Other commitment, period		20 years
Material cure period		60 days

Stockholder's Equity - Common S

Stockholder's Equity - Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from stock options exercised	$ 2.7	$ 2.7
2017 Long-Term Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options (in shares)	35,000
Exercise price of options (in dollars per share)	$ 7.25
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during the period (in shares)	448,847
Restricted stock issued ( in shares)	19,902
Stock issued from converted debt ( in shares )	155,916
Conversion price par value (in dollars per share)	$ 19.64
Cashless exercise of stock (in shares)	27,076
Exercise of stock options (in shares)	448,847	12,157
Proceeds from stock options exercised and warrant exercises		$ 0.7
Exercise of warrants (in shares)	71,667	59,510

Stockholder's Equity - Stock Op

Stockholder's Equity - Stock Options (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 09, 2021	Jul. 08, 2021	Jan. 01, 2021	Sep. 08, 2017
2017 Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)						400,000
Award vesting period	4 years
Expiration period	10 years
Shares available for issuance was increased percent					4.00%
Share-based compensation arrangement by represents an increase (in shares)		170,324
Shares available for future issuance (in shares)	104,255
Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)			100,000	100,000

Stockholder's Equity - Schedule

Stockholder's Equity - Schedule of Pre-2017 Non-Qualified Stock Options Outstanding (Details) - Pre-2017 Non-Qualified Stock Options - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Outstanding at beginning of period (in shares)	2,465,500	2,500,500
Exercised (in shares)	(480,002)	(20,000)
Forfeited (in shares)	(34,998)	(15,000)
Outstanding at end of period (in shares)	1,950,500	2,465,500	2,500,500
Exercisable (in shares)	1,950,500
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 6.99	$ 7.03
Exercised (in dollars per share)	5.86	9.50
Forfeited (in dollars per share)	10	10
Outstanding at end of period (in dollars per share)	7.17	$ 6.99	$ 7.03
Exercisable (in dollars per share)	$ 7.17
Weighted- average Remaining Contractual Term (years)
Outstanding	3 years 4 months 24 days	4 years 1 month 2 days	5 years 18 days
Exercisable	3 years 4 months 24 days
Aggregate Intrinsic Value
Outstanding	$ 51,602,190	$ 2,773,190	$ 18,426,325
Exercisable	$ 51,602,190

Stockholder's Equity - Schedu_2

Stockholder's Equity - Schedule of 2017 Stock Options Valuation Assumptions (Details) - Employee Stock Option - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
2017 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date	$ 8.20	$ 8.79
Risk-free interest rate	0.50%	0.33%
Volatility factor	76.00%	91.00%
Term (years)	5 years 6 months	5 years 6 months
2017 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date	$ 24.75	$ 13.60
Risk-free interest rate	1.30%	1.68%
Volatility factor	89.00%	101.00%
Term (years)	6 years 3 months	6 years 3 months
Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date	$ 16.41
Risk-free interest rate	0.84%
Dividend yield	0.00%
Volatility factor	76.26%
Term (years)	6 years 3 months

Stockholder's Equity - Schedu_3

Stockholder's Equity - Schedule of 2017 Plan Options Outstanding (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
2017 Plan
Number of Shares
Outstanding at beginning of period (in shares)	611,760	491,950
Granted (in shares)	163,285	191,500
Expired (in shares)	(3,845)	0
Forfeited (in shares)	(12,142)	(71,690)
Outstanding at end of period (in shares)	759,058	611,760	491,950
Exercisable (in shares)	513,279
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 21.39	$ 24.08
Granted (in dollars per share)	12.4	12.12
Exercised (in dollars per share)	19.49	0
Forfeited (in dollars per share)	12.60	15.05
Outstanding at end of period (in dollars per share)	19.61	$ 21.39	$ 24.08
Exercisable (in dollars per share)	$ 22.84
Weighted- average Remaining Contractual Term (years)
Outstanding	7 years 3 months 21 days	7 years 10 months 6 days	8 years 5 months 4 days
Exercisable	6 years 8 months 19 days
Aggregate Intrinsic Value
Outstanding	$ 10,997,428,000	$ 0	$ 81,888,000
Exercisable	$ 5,895,856,000
Inducement Equity Incentive Plan
Number of Shares
Outstanding at beginning of period (in shares)	0
Granted (in shares)	56,500
Expired (in shares)	0
Forfeited (in shares)	0
Outstanding at end of period (in shares)	56,500	0
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share)
Granted (in dollars per share)	16.41
Exercised (in dollars per share)
Forfeited (in dollars per share)
Outstanding at end of period (in dollars per share)	$ 16.41
Weighted- average Remaining Contractual Term (years)
Outstanding	9 years 6 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 972,930,000

Stockholder's Equity - Narrativ

Stockholder's Equity - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	56,500
Inducement Equity Incentive Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	56,500
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	$ 1,000
Granted (in shares)	163,285	191,500
Employee Stock Option | Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 200
Compensation cost not yet recognized	400
Employee Stock Option | 2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1,700	$ 2,100
Employee Stock Option | Pre-2017 Non-Qualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0	1,235
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	800	$ 200
Compensation cost not yet recognized	$ 500
Granted (in shares)	76,268,000	49,600,000
Restricted stock units | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Restricted stock units | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Restricted stock units | Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 100
Compensation cost not yet recognized	$ 1,200
Restricted Stock | Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	49,800

Stockholder's Equity - Schedu_4

Stockholder's Equity - Schedule of Restricted Stock Units Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted stock units
Number of Shares
Outstanding at beginning of period (in shares)	49,600,000	27,000,000
Granted (in shares)	76,268,000	49,600,000
Forfeited (in shares)	(1,550,000)	(27,000,000)
Vested (in share)	(19,902,000)
Outstanding at end of period (in shares)	104,416,000	49,600,000
Grant Date Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 12	$ 14.51
Granted (in dollars per share)	12.47	12
Forfeited (in dollars per share)	12.15	14.51
Vested (in dollars per share)	10.79
Outstanding at end of period (in dollars per share)	$ 12.57	$ 12
Inducement Equity Incentive Plan | Restricted Stock
Number of Shares
Outstanding at beginning of period (in shares)	0
Granted (in shares)	49,800
Vested (in share)
Outstanding at end of period (in shares)	49,800	0
Grant Date Fair Value Per Share
Outstanding at beginning of period (in dollars per share)
Granted (in dollars per share)	26.98
Vested (in dollars per share)
Outstanding at end of period (in dollars per share)	$ 26.98

Stockholder's Equity - Schedu_5

Stockholder's Equity - Schedule of Warrants Outstanding (Details) - Warrant - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Outstanding at beginning of period (in shares)	278,800	342,610
Exercised (in share)	0	(59,510)
Forfeited (in shares)	0	(4,300)
Outstanding at end of period (in shares)	278,800	278,800	342,610
Exercisable (in shares)	278,800
Grant Date Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 9.72	$ 9.77
Exercised (in dollars per share)	0	10
Forfeited (in dollars per share)	0	10
Outstanding at end of period (in dollars per share)	9.72	$ 9.72	$ 9.77
Exercisable (in dollars per share)	$ 9.72
Weighted- average Remaining Contractual Term (years)
Outstanding	2 years 6 months 3 days	3 years 6 months 3 days	3 years 8 months 15 days
Exercisable weighted average remaining contractual terms	2 years 6 months 3 days
Aggregate Intrinsic Value
Outstanding	$ 6,665,644	$ 1,164	$ 1,585,084
Exercisable aggregate intrinsic value	$ 6,665,644

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes & Net Deferred Tax (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 7,273,220		$ 3,192,777
Income Tax Reconciliation
Net loss before taxes at statutory rate	860,542	$ (352,562)
Permanent items	(575,449)	479,115
Temporary items	(420,274)	312,649
Income tax expense at statutory rate	(135,181)	439,202
Valuation allowance	159,451	(864,881)
Income tax expense (benefit) per books	24,270	(425,679)
Deferred Tax Assets Components
Net operating loss carryover at statutory rate	4,497,897	3,881,105
Stock-based compensation expense	3,544,938	2,923,099
Fixed asset depreciation	(18,378)	(38,863)
Intangibles amortization	(1,134)	(1,081)
Other	3,391	307,044
Total	8,026,714	7,071,304
Valuation allowance	(8,026,714)	(7,071,304)
Net deferred tax asset	0	0
Unrecognized tax benefits	$ 0	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jan. 24, 2022	Jan. 04, 2022	Dec. 11, 2020	Sep. 19, 2018	Mar. 15, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 10, 2020
Common Stock
Subsequent Event [Line Items]
Conversion price par value (in dollars per share)						$ 19.64
Exercise of stock options (in shares)						448,847	12,157
Loan Agreement
Subsequent Event [Line Items]
Debt conversion, original debt, amount						$ 3,100,000
Aggregate principal amount								$ 50,000,000
Conversion price par value (in dollars per share)								$ 19.64
Loan Agreement | Tranche One
Subsequent Event [Line Items]
Aggregate principal amount								$ 20,000,000
Loan Agreement | Tranche Two
Subsequent Event [Line Items]
Aggregate principal amount								10,000,000
Loan Agreement | Tranche Three
Subsequent Event [Line Items]
Aggregate principal amount								$ 20,000,000
Biomedical Advanced Research and Development Authority (BARDA)
Subsequent Event [Line Items]
Proceeds from funding agreement			$ 3,500,000	$ 4,600,000
Restricted stock units
Subsequent Event [Line Items]
Vested (in share)						19,902,000
Restricted stock units | Tranche One
Subsequent Event [Line Items]
Vesting percentage						25.00%
Restricted stock units | Tranche Two
Subsequent Event [Line Items]
Vesting percentage						25.00%
Subsequent Event
Subsequent Event [Line Items]
Exercise of stock options (in shares)					7,097
Subsequent Event | Pontifax Medisen Finance | Common Stock
Subsequent Event [Line Items]
Debt conversion, converted instrument, Issued( in share)					70,000
Conversion price par value (in dollars per share)					$ 19.64
Subsequent Event | Kreos Capital | Common Stock
Subsequent Event [Line Items]
Debt conversion, converted instrument, Issued( in share)					50,916
Conversion price par value (in dollars per share)					$ 19.64
Subsequent Event | Loan Agreement | Pontifax Medisen Finance
Subsequent Event [Line Items]
Debt conversion, original debt, amount					$ 1,400,000
Aggregate principal amount					7,900,000
Subsequent Event | Loan Agreement | Kreos Capital
Subsequent Event [Line Items]
Debt conversion, original debt, amount					1,000,000
Aggregate principal amount					$ 9,000,000
Subsequent Event | Biomedical Advanced Research and Development Authority (BARDA)
Subsequent Event [Line Items]
Proceeds from funding agreement	$ 2,200,000
Subsequent Event | Restricted stock units
Subsequent Event [Line Items]
Vested (in share)					31,746
Subsequent Event | Employee | Restricted stock units
Subsequent Event [Line Items]
Issuance of restricted common shares(in share)		135,475
Market value of stock on measurement date (in dollars per share)		$ 32.85
Award vesting period		3 years
Subsequent Event | Employee | Restricted stock units | Tranche One
Subsequent Event [Line Items]
Vesting percentage		33.00%
Subsequent Event | Employee | Restricted stock units | Tranche Two
Subsequent Event [Line Items]
Vesting percentage		33.00%
Subsequent Event | Employee | Restricted stock units | Tranche Three
Subsequent Event [Line Items]
Vesting percentage		33.00%
Subsequent Event | Employee | Performance Shares
Subsequent Event [Line Items]
Issuance of restricted common shares(in share)		80,735
Market value of stock on measurement date (in dollars per share)		$ 32.85
Vesting percentage		25.00%